소화기 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약제 종류별, 약물 종류별, 투여 경로별, 용도별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Gastrointestinal Therapeutics Market Summary

The global gastrointestinal therapeutics market size was estimated at USD 42.75 billion in 2025 and is projected to reach USD 51.45 billion by 2033, growing at a CAGR of 2.2% from 2026 to 2033. The industry is expanding due to the rising incidence of digestive disorders across both developed and emerging regions.

The increasing prevalence of gastroesophageal reflux disease, irritable bowel syndrome, inflammatory bowel disease, and peptic ulcer disorders is strengthening the demand for long-term pharmacological management. Rapid urbanization, processed food consumption, irregular eating patterns, and elevated stress exposure are contributing to persistent gastrointestinal complications. A larger diagnosed patient population is seeking continuous symptom relief and disease control therapies. Higher consultation rates in primary and specialty care settings are further supporting prescription volumes.

Growing awareness regarding early symptom recognition is encouraging timely treatment initiation. For instance, in January 2026, Current Gastroenterology Reports, a Springer publication, reviewed acute severe ulcerative colitis and reported that intravenous corticosteroid therapy, used for about 70 years remained associated with colectomy rates of 25% to 30%, while severe flares occurred in 25% to 50% of patients during their disease course and 20% presented with a severe flare initially. The analysis further noted cumulative colectomy rates rising from 19.9% after the first admission to 38.6% after four admissions, and first year mortality of 40% to 75% in the pre steroid era, which declined to below 1% in the modern era, yet increased to about 5% in older or refractory cases, underscoring significant unmet clinical need.

Advancements in pharmaceutical research and product innovation are significantly contributing to market growth. Development of biologics, targeted small molecules, and improved acid suppression therapies is enhancing clinical outcomes for chronic gastrointestinal conditions. Novel drug delivery systems are improving absorption profiles and reducing adverse effects, strengthening patient adherence. Precision based treatment strategies are supporting individualized therapeutic regimens in inflammatory bowel disease and related disorders.

Global Gastrointestinal Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global gastrointestinal therapeutics market report based on drug type, drug class, route of administration, application, distribution channel, and region:

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded
• Generics
• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Aminosalicylates
• Digestive Enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-emetics
• H2 Antagonists
• Anti-diarrheals
• Biologics/ Biosimilar
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectables
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Application
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Gastrointestinal Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Gastrointestinal Therapeutics Market: Drug Type Business Analysis

• 4.1. Drug Type Market Share, 2025 & 2033
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
• 4.4. Branded
  • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
• 4.5. Generics
  • 4.5.1. Generics Market, 2021 - 2033 (USD Million)

Chapter 5. Gastrointestinal Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2025 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug class, 2021 to 2033 (USD Million)
• 5.4. Aminosalicylates
  • 5.4.1. Aminosalicylates Market, 2021 - 2033 (USD Million)
• 5.5. Digestive Enzymes
  • 5.5.1. Digestive Enzymes Market, 2021 - 2033 (USD Million)
• 5.6. Proton Pump Inhibitors
  • 5.6.1. Proton Pump Inhibitors Market, 2021 - 2033 (USD Million)
• 5.7. Laxatives
  • 5.7.1. Laxatives Market, 2021 - 2033 (USD Million)
• 5.8. Anti-emetics
  • 5.8.1. Anti-emetics Market, 2021 - 2033 (USD Million)
• 5.9. H2 Antagonists
  • 5.9.1. H2 Antagonists Market, 2021 - 2033 (USD Million)
• 5.10. Anti-diarrheals
  • 5.10.1. Anti-diarrheals Market, 2021 - 2033 (USD Million)
• 5.11. Biologics/Biosimilar
  • 5.11.1. Biologics/Biosimilar Market, 2021 - 2033 (USD Million)
• 5.12. Others
  • 5.12.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Gastrointestinal Therapeutics Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2021 - 2033 (USD Million)
• 6.5. Injectables
  • 6.5.1. Injectables Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Gastrointestinal Therapeutics Market: Application Business Analysis

• 7.1. Application Market Share, 2025 & 2033
• 7.2. Application Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 7.4. Crohn's disease
  • 7.4.1. Crohn's disease Market, 2021 - 2033 (USD Million)
• 7.5. Ulcerative colitis
  • 7.5.1. Ulcerative colitis Market, 2021 - 2033 (USD Million)
• 7.6. GERD
  • 7.6.1. GERD Market, 2021 - 2033 (USD Million)
• 7.7. IBS
  • 7.7.1. IBS Market, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Gastrointestinal Therapeutics Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2025 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 9. Gastrointestinal Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Gastrointestinal Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. Canada Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. UK Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Brazil Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. Argentina Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Gastrointestinal Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. AbbVie Inc.
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. AstraZeneca
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Salix Pharmaceuticals
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Takeda Pharmaceutical Company Limited
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Pfizer Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Bayer AG
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Abbott
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Janssen Pharmaceuticals NV
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Sun Pharmaceutical Industries Ltd.
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Cipla Inc.
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives
  • 10.5.11. Gilead Sciences, Inc.
    • 10.5.11.1. Overview
    • 10.5.11.2. Financial Performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Strategic Initiatives